Minoo Battiwalla

List of Publications by Year
in descending order

119 papers	2,882 citations	201385 27 h-index	174990 52 g-index
122 all docs	122 docs citations	122 times ranked	4482 citing authors

#	Article	IF	Citations
1	Increasing Incidence of Chronic Graft-versus-Host Disease inÂAllogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 266-274.	2.0	331
2	HLA-C Antigen Mismatch Is Associated with Worse Outcome in Unrelated Donor Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 885-892.	2.0	196
3	Prevention and Early Treatment of Invasive Fungal Infection in Patients with Cancer and Neutropenia and in Stem Cell Transplant Recipients in the Era of Newer Broad-Spectrum Antifungal Agents and Diagnostic Adjuncts. Clinical Infectious Diseases, 2007, 44, 402-409.	2.9	166
4	Mesenchymal stem cells in hematopoietic stem cell transplantation. Cytotherapy, 2009, 11, 503-515.	0.3	163
5	Relapse after allogeneic stem cell transplantation. Expert Review of Hematology, 2010, 3, 429-441.	1.0	154
6	Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers. Molecular Therapy, 2014, 22, 1388-1395.	3.7	106
7	Immunotherapy for Fungal Infections. Clinical Infectious Diseases, 2006, 42, 507-515.	2.9	91
8	Bone Marrow Mesenchymal Stromal Cells to Treat Tissue Damage in Allogeneic Stem Cell Transplant Recipients: Correlation of Biological Markers with Clinical Responses. Stem Cells, 2014, 32, 1278-1288.	1.4	83
9	HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 1783-1789.	2.0	83
10	Improved survival after acute graft- versus -host disease diagnosis in the modern era. Haematologica, 2017, 102, 958-966.	1.7	79
11	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report. Biology of Blood and Marrow Transplantation, 2017, 23, 201-210.	2.0	79
12	Human herpes 6 virus encephalitis complicating allogeneic hematopoietic stem cell transplantation. Neurology, 2013, 80, 1494-1500.	1.5	78
13	Ganciclovir Inhibits Lymphocyte Proliferation by Impairing DNA Synthesis. Biology of Blood and Marrow Transplantation, 2007, 13, 765-770.	2.0	74
14	Female Long-Term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation: Evaluation and Management. Seminars in Hematology, 2012, 49, 83-93.	1.8	65
15	Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure. Biology of Blood and Marrow Transplantation, 2004, 10, 49-57.	2.0	56
16	The clinical and financial burden of pre-emptive management ofÂcytomegalovirus disease after allogeneic stem cell transplantationâ€"implications for preventative treatment approaches. Cytotherapy, 2014, 16, 927-933.	0.3	56
17	Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. Biology of Blood and Marrow Transplantation, 2016, 22, 1493-1503.	2.0	55
18	HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders. British Journal of Haematology, 2003, 123, 449-453.	1.2	54

#	Article	IF	Citations
19	Selectively T Cell-Depleted Allografts from HLA-Matched Sibling Donors Followed by Low-Dose Posttransplantation Immunosuppression to Improve Transplantation Outcome in Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2011, 17, 1855-1861.	2.0	52
20	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes. Biology of Blood and Marrow Transplantation, 2017, 23, 6-9.	2.0	49
21	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer, 2016, 122, 3005-3014.	2.0	45
22	The impact of HLA unidirectional mismatches on the outcome of myeloablative hematopoietic stem cell transplantation with unrelated donors. Blood, 2013, 121, 4800-4806.	0.6	44
23	Long-Term Survivorship after Hematopoietic Cell Transplantation: Roadmap for Research and Care. Biology of Blood and Marrow Transplantation, 2017, 23, 184-192.	2.0	40
24	Recombinant Human Factor VIIa for Alveolar Hemorrhage Following Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 969-978.	2.0	37
25	Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1589-1596.	2.0	37
26	Quantitative activation suppression assay to evaluate human bone marrowâ€“derived mesenchymal stromal cell potency. Cytotherapy, 2015, 17, 1675-1686.	0.3	31
27	Immune Reconstitution in Recipients of Photodepleted HLA-Identical Sibling Donor Stem Cell Transplantations: T Cell Subset Frequencies Predict Outcome. Biology of Blood and Marrow Transplantation, 2011, 17, 1846-1854.	2.0	28
28	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Advances, 2018, 2, 933-940.	2.5	27
29	Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence. Blood, 2006, 107, 1970-1973.	0.6	26
30	Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events. Experimental Hematology, 2014, 42, 83-89.	0.2	26
31	When the Minimal Becomes Measurable. Journal of Clinical Oncology, 2016, 34, 2557-2558.	0.8	26
32	Epigenetic landscape of the <scp>TERT</scp> promoter: a potential biomarker for high risk <scp>AML</scp>/<scp>MDS</scp>. British Journal of Haematology, 2016, 175, 427-439.	1.2	25
33	Acute myeloid leukemia and diabetes insipidus with monosomy 7. Cancer Genetics and Cytogenetics, 2009, 190, 97-100.	1.0	22
34	Multiparameter flow cytometry for the diagnosis and monitoring of small GPIâ€deficient cellular populations. Cytometry Part B - Clinical Cytometry, 2010, 78B, 348-356.	0.7	22
35	Donor lymphocyte count and thymic activity predict lymphocyte recovery and outcomes after matched-sibling hematopoietic stem cell transplant. Haematologica, 2013, 98, 346-352.	1.7	22
36	A Comparison of Measured Creatinine Clearance versus Calculated Glomerular Filtration Rate for Assessment of Renal Function before Autologous and Allogeneic BMT. Biology of Blood and Marrow Transplantation, 2009, 15, 574-579.	2.0	21

#	Article	IF	Citations
37	Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. Haematologica, 2014, 99, 1868-1875.	1.7	19
38	Evolution of the donor T-cell repertoire in recipients in the second decade after allogeneic stem cell transplantation. Blood, 2011, 117, 5250-5256.	0.6	18
39	Bone Marrow Mesenchymal Stromal Cells to Treat Complications Following Allogeneic Stem Cell Transplantation. Tissue Engineering - Part B: Reviews, 2014, 20, 211-217.	2.5	18
40	Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant. JAMA Oncology, 2020, 6, 696.	3.4	18
41	Immune Deficits in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients. Mycopathologia, 2009, 168, 271-282.	1.3	15
42	HLA DR15 Antigen Status Does Not Impact Graft-versus-Host Disease or Survival in HLA-Matched Sibling Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2012, 18, 1302-1308.	2.0	15
43	Pulmonary Histoplasma Infection After Allogeneic Hematopoietic Stem Cell Transplantation: Case Report and Review of the Literature. Open Forum Infectious Diseases, 2017, 4, ofx041.	0.4	14
44	Allogeneic transplantation using non-myeloablative transplant regimens. Best Practice and Research in Clinical Haematology, 2001, 14, 701-722.	0.7	13
45	Repair of Impaired Pulmonary Function Is Possible in Very-Long-Term Allogeneic Stem Cell Transplantation Survivors. Biology of Blood and Marrow Transplantation, 2014, 20, 209-213.	2.0	13
46	Over-expression of PD-1 Does Not Predict Leukemic Relapse after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 216-222.	2.0	11
47	Upsetting the apple CARâ€T (chimeric antigen receptor Tâ€cell therapy) â€sustainability mandates USA innovation. British Journal of Haematology, 2020, 190, 851-853.	1.2	11
48	T Cell Exhaustion and Downregulation of Cytotoxic NK Cells â€“ an Immune Escape Mechanism in Adult Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3781-3781.	0.6	11
49	A Rare Consequence of Chronic Graft Versus Host Disease - Peyronie's Disease. Archives in Cancer Research, 2015, 3, .	0.3	9
50	Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure. Biology of Blood and Marrow Transplantation, 2015, 21, 1790-1795.	2.0	9
51	Reprint of: Long-Term Survivorship after Hematopoietic Cell Transplantation: Roadmap for Research and Care. Biology of Blood and Marrow Transplantation, 2017, 23, S1-S9.	2.0	9
52	Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia. Molecular Therapy, 2016, 24, 1655-1664.	3.7	8
53	Clinical and biological predictors of outcome following relapse of CML post-allo-SCT. Bone Marrow Transplantation, 2015, 50, 189-196.	1.3	7
54	Clinical and Pathological Presentation of T-Cell Large Granular Lymphocyte Proliferations (T-LGL): A Single Institution Experience.. Blood, 2004, 104, 3865-3865.	0.6	7

#	Article	IF	Citations
55	Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia. Leukemia and Lymphoma, 2012, 53, 2085-2088.	0.6	6
56	HLA-Matched Sibling Transplantation for Severe Aplastic Anemia: Impact of HLA DR15 Antigen Status on Engraftment, Graft-versus-Host Disease, and Overall Survival. Biology of Blood and Marrow Transplantation, 2012, 18, 1401-1406.	2.0	6
57	CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation. Supportive Care in Cancer, 2016, 24, 815-822.	1.0	6
58	High Frequency and Early Onset of Bone Mineral Density Loss Following Allogeneic Stem Cell Transplantation.. Blood, 2005, 106, 2011-2011.	0.6	6
59	Radiation exposure from diagnostic procedures following allogeneic stem cell transplantation â€“ How much is acceptable?. Hematology, 2014, 19, 275-279.	0.7	5
60	Ex vivo T-cellâ€“depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy. Cytotherapy, 2017, 19, 735-743.	0.3	5
61	Cellular immune profiling after sequential clofarabine and lenalidomide for high risk myelodysplastic syndromes and acute myeloid leukemia. Leukemia Research Reports, 2017, 7, 40-44.	0.2	5
62	Myeloid Leukemias Directly Suppress T Cell Proliferation Through STAT3 and Arginase Pathways. Blood, 2013, 122, 3885-3885.	0.6	5
63	BuCy Provides Equivalent Outcomes to VCyTBI as Conditioning Prior to Auto-SCT in Patients with Relapsed/Refractory NHL and Is a Valuable Option in Older (â‰¥60 years) Patients.. Blood, 2008, 112, 2176-2176.	0.6	4
64	Mesenchymal Stem Cells in Hematopoietic Stem Cell Transplantation. , 2012, , 101-115.		3
65	Distinct Biomarker Profiles in Ex Vivo T Cell Depletion Graft Manipulation Strategies: CD34+ Selection versus CD3+/19+ Depletion in Matched Sibling Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 460-466.	2.0	3
66	HLA DR15 and Immunobiologic Outcomes. Biology of Blood and Marrow Transplantation, 2007, 13, 371.	2.0	2
67	Human leukocyte antigen DR4 is associated with inferior progression-free survival following allogeneic hematopoietic stem cell transplantation for lymphoid malignancies. Leukemia and Lymphoma, 2008, 49, 1494-1500.	0.6	2
68	Acquired RhD mosaicism identifies fibrotic transformation of thrombopoietin receptor-mutated essential thrombocythemia. Transfusion, 2017, 57, 2136-2139.	0.8	2
69	Persistence of skewed X-chromosome inactivation in pre-B acute lymphoblastic leukemia of a female ATRX mutation carrier. Blood Advances, 2019, 3, 2627-2631.	2.5	2
70	Impact of Age on Transfusion Independence Response, Survival, and Transformation to Acute Myeloid Leukemia in Patients with Deletion 5q: A Sub-Analysis of the MDS-003 Study. Blood, 2008, 112, 5071-5071.	0.6	2
71	Impact of Baseline Renal Function on Transfusion-Independence Response, Survival, and Transformation to Acute Myeloid Leukemia in Patients with Deletion 5q: A Sub-Analysis of the MDS-003 Study. Blood, 2008, 112, 5088-5088.	0.6	2
72	Ultra-Low Dose IL-2 Safely Expands Regulatory T Cells and CD56bright NK Cells in Healthy Volunteers: Towards Safer Stem Cell Donors?. Blood, 2012, 120, 3283-3283.	0.6	2

#	Article	IF	Citations
73	Early CMV Reactivation Still Remains a Cause of Increased Transplant Related Mortality in the Current Era: A CIBMTR Analysis. Blood, 2014, 124, 47-47.	0.6	2
74	Selective Depletion of Alloreactive Donor T Cells with Adenosine: An Efficient, Scaleable, GMP-Compliant, Low-Cost Method to Prevent Gvhd While Preserving Antiviral and Antileukemic Activity in Haploidentical Stem Cell Transplant. Blood, 2015, 126, 380-380.	0.6	2
75	Framingham Risk Score Is an Ineffective Screening Strategy for Coronary Heart Disease in Long-Term Allogeneic Hematopoietic Cell Transplant Survivors. Clinical Hematology International, 2020, 2, 109.	0.7	2
76	Fatal Hyperacute Graft-versus-Host Disease following Denileukin Diftitox Treatment for Recurrent T Cell Lymphoma after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 887-890.	2.0	1
77	Safety Issues in MSC Therapy. , 2013, , 377-387.		1
78	Minor ABO Incompatibility Does Not Impact Nonrelapse Mortality in T Cellâ€“Depleted Human Leukocyte Antigenâ€“Matched Sibling Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 954-955.	2.0	1
79	Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016. Leukemia Research, 2017, 53, 8-12.	0.4	1
80	Borderline Donor Specific Antibodies Are Safe in Haploidentical Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, S204.	2.0	1
81	Role of G-CSF after High-Dose Post-Transplantation Cyclophospamide. Blood, 2018, 132, 3384-3384.	0.6	1
82	Association of Comprehensive Lipoprotein Profiling with Coronary Artery Disease in Allogeneic Stem Cell Transplant (Allo-SCT) Survivors. Blood, 2016, 128, 828-828.	0.6	1
83	Alemtuzumab Achieved Durable Hematologic Response In Heavily Treated T-Large Granular Lymphocytosis Irrespective To STAT3 Mutation Or V-Beta Clone Size. Blood, 2013, 122, 3705-3705.	0.6	1
84	T Cell Depleted Allogeneic Stem Cell Transplants for Hematological Malignancies: A 20 Year Experience Shows No Relationship Between Choice of Transplanted T Cell Dose or Delayed T Cell Add-Back on Major Outcomes. Blood, 2015, 126, 2013-2013.	0.6	1
85	Novel alternative for treating paroxysmal nocturnal hemoglobinuria in selected patients. Community Oncology, 2008, 5, 70.	0.2	0
86	T-cell large granular lymphocytosis associated with malignant thymoma. Leukemia Research, 2012, 36, e187-e189.	0.4	0
87	The Clinical and Financial Cost of Preemptive Management of CMV Disease â€“ Implications for Immunotherapy. Biology of Blood and Marrow Transplantation, 2014, 20, S128.	2.0	0
88	Abnl(17p) in AML: who will guard the guardian?. Blood, 2014, 123, 2906-2907.	0.6	0
89	Blood Stream Infection Is Frequent during Conditioning but Does Not Impact Allogeneic Transplant Outcomes in the Modern Era. Biology of Blood and Marrow Transplantation, 2015, 21, S268.	2.0	0
90	Minor ABO Incompatibility Does Not Impact Non-Relapse Mortality in T-Cell Depleted HLA-Matched Sibling Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, S276-S277.	2.0	0

#	Article	IF	Citations
91	Clinical and laboratory predictors impacting allogeneic peripheral blood stem cell mobilization. Cytotherapy, 2015, 17, S66.	0.3	0
92	Risk Factors for Human Papilloma Virus Reactivation in the Genital Tract of Female Stem Cell Transplant Survivors. Biology of Blood and Marrow Transplantation, 2016, 22, S26.	2.0	0
93	Fertility Preservation Prior to Myeloablative Allogeneic Peripheral Blood Stem Cell Transplant in Clinical Trials for Hematological Malignancies - Practical Challenges in Transplant Coordination. Biology of Blood and Marrow Transplantation, 2016, 22, S113-S114.	2.0	0
94	Improved Reproducibility of Gvhd Biomarker Assay- Application of Multiplex Microfluidic Channel System. Biology of Blood and Marrow Transplantation, 2016, 22, S388.	2.0	0
95	Hematologic Malignancy Recurrence in Female Reproductive Tract Seen on Routine Gynecologic Screening [25J]. Obstetrics and Gynecology, 2017, 129, 109S-109S.	1.2	0
96	Premature coronary artery disease following allogeneic stem cell transplantation: an NHLBI Cohort Study. Bone Marrow Transplantation, 2019, 54, 320-322.	1.3	0
97	How Sarah Cannon Blood Cancer Network (SCBCN) Uses Historical Data to Benchmark Survival, Transplant Related Mortality, Engraftment and GVHD for Performance Improvement. Biology of Blood and Marrow Transplantation, 2019, 25, S419.	2.0	0
98	Optimizing Plerixafor Algorithm for Mobilization of Peripheral Blood Stem Cells in Patients with Multiple Myeloma Requiring Tandem Transplants. Biology of Blood and Marrow Transplantation, 2019, 25, S218-S219.	2.0	0
99	Survivorship Issues: Practices, Guidelines and Controversies. Advances and Controversies in Hematopoietic Transplantation and Cell Therapy, 2020, , 201-219.	0.0	0
100	Autoimmune Disease (AD) in Patients with Myelodysplastic Syndrome (MDS): A Retrospective Single Institution Study.. Blood, 2004, 104, 4736-4736.	0.6	0
101	Immunosuppression for Myelodysplastic Syndrome: Association between a Score Based on Presenting Features and Long-Term Survival.. Blood, 2004, 104, 1431-1431.	0.6	0
102	Human T Lymphocyte Activation Kinetics for Identifying and Targeting Alloreactive T Cells.. Blood, 2005, 106, 5249-5249.	0.6	0
103	Ganciclovir Suppresses Human T Lymphocyte Proliferation In Vitro.. Blood, 2005, 106, 5378-5378.	0.6	0
104	Effect of Bone Marrow Hypoplasia Secondary to Reinduction Therapy for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) on Outcomes after Blood and Marrow Transplantation (BMT).. Blood, 2006, 108, 3033-3033.	0.6	0
105	Influence of Human Leukocyte Antigen Haplotypes on Acute Graft Versus Host Disease Incidence after Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2006, 108, 2887-2887.	0.6	0
106	Glutathione-S-Transferase M1 (GSTM1) and T1 (GSTT1) Single Nucleotide Polymorphisms (SNPs) Predict Regimen-Related Toxicity after Autologous and Allogeneic Blood and Marrow Transplantation (BMT).. Blood, 2006, 108, 47-47.	0.6	0
107	Fluorescence Activated Cell Sorting (FACS) Followed by Fluorescence In Situ Hybridization (FISH) To Determine Clonal Origins of Cells in Myelodysplastic Syndrome (MDS) with Paroxysmal Nocturnal Hemoglobinuria (PNH).. Blood, 2007, 110, 4623-4623.	0.6	0
108	Clinical and Genetic Factors Underlying Acute Bone Mineral Density Loss by 100 Days after Blood and Marrow Transplantation: A Potential Early Regimen-Related Complication. Blood, 2008, 112, 52-52.	0.6	0

#	Article	IF	Citations
109	Modulation of Immune Function. , 2009, , 234-258.		0
110	Second Stem Cell Transplantation (SCT) for Relapsed Leukemia Provides Only Modest Prolongation of Survival. Blood, 2011, 118, 2001-2001.	0.6	0
111	Transplantation For Myelodysplastic Syndrome Evolving From Aplastic Anemia Treated With Immunosuppressive Therapy: From The Fred Hutchinson Cancer Research Center and Center For International Bone Marrow Transplantation Research. Blood, 2013, 122, 924-924.	0.6	0
112	CD34+ Selection Avoids Methotrexate and Reduces the Severity of Oral Mucositis in TBI-Based Allogeneic Stem Cell Transplantation. Blood, 2014, 124, 3898-3898.	0.6	0
113	Clinical Comorbidity Measures and Predictive Scores in Ex Vivo T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 2550-2550.	0.6	0
114	A Novel Standardized Quantitative Suppression Assay Reveals a Diversity of Human Immune-Regulatory Cell Potency. Blood, 2014, 124, 316-316.	0.6	0
115	Activity of the Telomerase Inhibitor GRN163L (Imetelstat) on Acute Myeloblastic Leukemia Blasts Is Enhanced By DNA Methyltransferase Inhibitors Irrespective of TERT Promoter Methylation Status. Blood, 2015, 126, 1267-1267.	0.6	0
116	Comparison of Donor KIR Genotype, Recipient CMV Reactivation and Pretransplant MRD in Predicting Relapse after Ex Vivo T-Deplete Allohsct. Blood, 2015, 126, 3212-3212.	0.6	0
117	Safety and Feasibility of Ultra-Low Dose IL-2 As Graft Versus Host Disease Prophylaxis in Haplo-Identical Stem Cell Transplantation- a Proof of Concept Pilot Study. Blood, 2016, 128, 386-386.	0.6	0
118	Neoantigen Landscape of Relapsed Acute Leukemia Following Allogeneic Stem Cell Transplantation. Blood, 2018, 132, 4595-4595.	0.6	0
119	Center Effects on Outcomes in the Treatment of Acute Myelogenous Leukemia (AML): A Multilevel, Community-Based, Case-Controlled Study. Blood, 2019, 134, 4780-4780.	0.6	0